Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. - Wikidata - wikimedia - TriplyDB

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

http://www.wikidata.org/entity/Q38442153

about

Hemostatic management of patients undergoing ear-nose-throat surgery A Meta-Analysis of Randomized Clinical Trials Comparing Shorter (Less or Equal Than 6 Months) and Longer (More or Equal Than 12 Months) Dual Anti-Platelet Therapy Following Drug-Eluting Coronary Stents Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression.Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis Can phone-based motivational interviewing improve medication adherence to antiplatelet medications after a coronary stent among racial minorities? A randomized trial.Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis.Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2.Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials Recent advances in the diagnosis and treatment of acute myocardial infarction Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial Management of the patient with an acute coronary syndrome using oral anticoagulation.Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies.Efficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis.Current Practices Regarding Perioperative Management of Patients With Fracture on Antiplatelet Therapy: A Survey of Orthopedic Surgeons.Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents.Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium ste Pregnancy in women after coronary revascularization Organ transplantation and drug eluting stents: Perioperative challenges.Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation.Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration.Perioperative management and monitoring of antiplatelet agents: a focused review on aspirin and P2Y12 inhibitors Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies.

P2860

Q26771864-F75F4FA3-FCD0-415B-A3A3-360D1C8A524B Q26784131-638DDB06-3659-4F8F-84D0-81B44A085582 Q26785321-1EF6FB44-DB98-4D5E-B1C7-4BCFE3921970 Q26852812-0E647CB4-17DA-4BBD-B395-6F24165A7BD7 Q26866350-2B53A13E-1D3C-4610-BC61-2D8DC459B4D8 Q28072522-AC640725-44FB-46B8-B165-CDB2B69C93BE Q28552288-6B792A9B-3A0E-4BA4-9548-C4249FCA40C8 Q30239889-6F5875C7-EB54-4E90-B9E7-402AB5CDE7F3 Q30241829-7A1BCFCB-9849-4E32-ADD6-C4E770A88915 Q31043715-8D455443-2E89-470F-8B84-0AA14C08279C Q31155795-DD0339B4-F751-4B0C-BD0B-D36D32C70A69 Q33613297-847CA6DF-9AC7-42B5-9B83-4F9A2C9C299D Q33642986-0DC5DC74-A6D2-449D-B0F5-63FD83971742 Q34046881-AC892A65-5978-4FFD-9993-907616FA0C6A Q34055438-0575CFE6-6242-4A0A-B0B4-C1D1D411C420 Q35070809-00764F4F-FAD2-4A4D-8ED3-96C3F61D0F7A Q35210009-1CD53EDD-B24D-4939-9296-CBB1FA7C0421 Q35283386-A4EBEF4A-EA70-4F04-BF9D-6A30940C0C4F Q35324208-D025580D-88EF-42F7-BB0F-CB073FD0BE50 Q35530065-60F3A459-6075-45A4-9425-78F089229B8E Q35541045-575E4BBF-0F61-45BE-A824-5FCBBC079B5F Q35626702-FCDEE16F-15B8-4E2F-B64E-7A9285D0F464 Q35783487-84772DCC-C6F2-4627-9D64-223EFF7E64AB Q35783499-94A3A347-78A2-40BA-9025-DD0A8F464DD2 Q35991815-AC0AC1F6-5B0D-4AC0-9A85-B508400168D7 Q36086140-B113C2EE-912E-4FEF-8BB2-7DD38CE26BE4 Q36117653-DB487515-4A09-43E5-80F5-03F57BB7B511 Q36237726-3B186627-203B-4E46-B120-3FAC1F188B97 Q36285820-F3B30F39-0DB9-4893-98CC-7FDAB13012BE Q36347982-48865D18-6A62-44BE-9E5F-7D8A356DB04F Q36369122-269C7A18-F192-41D7-90DD-4F2AA145CA7F Q36624476-F2A7A5DD-9FE8-466B-AD1E-D87F57DAFB4A Q36682317-E4A524C1-10A5-4FFA-893F-19DAB7762232 Q37043053-24238A23-508C-4734-9E47-AAC6F07EEC7D Q37070397-EF792467-C233-4FDC-A72A-2CD68D61B061 Q37522553-3139F567-CAEB-44DB-A00F-EC95E22E3CF7 Q38176288-09EB1600-54F6-4709-A132-3B65C2BABE1B Q38297800-7E2C8EC8-033E-43A7-BF98-40488880468A Q38631422-2FA3B018-5DEE-4C5B-8CC0-3E08BA920424 Q38635747-2FD614C1-DB03-4896-8AC5-402116B682C3

P2860

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

http://www.wikidata.org/entity/Q38442153

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Three vs twelve months of dual ...... the OPTIMIZE randomized trial.

@en

type

label

Three vs twelve months of dual ...... the OPTIMIZE randomized trial.

@en

prefLabel

Three vs twelve months of dual ...... the OPTIMIZE randomized trial.

@en

P1433

Q38442153-D06BFD94-FF73-48AF-89E8-D2ED83E763FB

P1476

Q38442153-A2370DF3-6447-4F3A-A327-870CE8B8DD8A

P2093

Q38442153-03920100-3C4D-4C56-82BC-DB39081805FE

Q38442153-053907F3-ADB1-4739-8505-BC2E776032B2

Q38442153-113B2C69-298B-4A3A-837B-B3C80684747B

Q38442153-21900898-04EB-489D-9542-73C6C5E986DB

Q38442153-2A742C9D-B6D9-48DD-966D-A677328DFB26

Q38442153-2CA21464-55B6-425E-9738-4BF3851BBBB6

Q38442153-403D654D-48FE-433D-8375-6B2AE3707560

Q38442153-4E0EB521-053D-4BC6-B990-4579E0F46876

Q38442153-593053D5-BDEF-4F73-AE4D-1F74FE03B45C

Q38442153-5CAD0AA4-2864-4EAA-83D5-F10B551F953F

P304

Q38442153-A9C2D16D-A64B-44F5-A56A-471C4A8120AC

P31

Q38442153-1BB67FF0-9775-4DA1-8F69-D8BB2EE8852D

P356

Q38442153-D2CF631A-1AB7-432B-981E-641B616D71B0

P407

Q38442153-98FB54C5-332B-462B-94EE-45F7A4F3E612

P433

Q38442153-60245F2D-C74D-4F57-864A-14F0CCBDDCD4

P478

Q38442153-FB6ADEE1-1CCB-48B7-9F26-FAEC6A17FA6E

P577

Q38442153-6DC4B959-1359-4254-8106-4B5B5E498C64

P5875

Q38442153-3DE1F923-23B5-4090-AE0C-1538982C8717

P698

Q38442153-28F6674F-5450-45FE-9896-AE8F196CC549

P356

JAMA.2013.282183

P1433

Journal of the American Medical Association

P1476

Three vs twelve months of dual ...... the OPTIMIZE randomized trial.

@en

P2093

Alexandre Abizaid

http://www.w3.org/2001/XMLSchema#string

Andrea S Abizaid

http://www.w3.org/2001/XMLSchema#string

André Labrunie

http://www.w3.org/2001/XMLSchema#string

Deepak L Bhatt

http://www.w3.org/2001/XMLSchema#string

Décio Salvadori

http://www.w3.org/2001/XMLSchema#string

Eduardo L Nicolela

http://www.w3.org/2001/XMLSchema#string

Fausto Feres

http://www.w3.org/2001/XMLSchema#string

Fernando S Devito

http://www.w3.org/2001/XMLSchema#string

George X Meireles

http://www.w3.org/2001/XMLSchema#string

Hélio J Castello

http://www.w3.org/2001/XMLSchema#string

P304

2510-2522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2013.282183

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

310

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262044959

http://www.w3.org/2001/XMLSchema#string

P698

24177257

http://www.w3.org/2001/XMLSchema#string